pembrolizumab
merck
['melanoma', 'pembro']
insightful data. neoadjvuant versus adjuvant pembrolizumab for resected stage iii-iv melanoma (swog s1801). 2-year efs: 72% vs 49% #esmo2022 #paris 
28. MD. PhD student. Medical Oncology trainee at Ramón y Cajal University Hospital (Madrid). ???? ????????? Avid traveller! ????